Hydroxyflutamide responses depend on the receptor and assay context. It showed agonist behavior in a wild-type AR CV1 reporter assay under R1881 cotreatment. In LNCaP cells carrying AR T877A, 1 μM hydroxyflutamide for 72 hours increased the WST-1 growth-associated signal versus ethanol control, while bicalutamide did not stimulate this endpoint. [1,3]
Whole-cell androgen-receptor ligand displacement
Cell-based study · HEK293 cells transiently expressing wild-type human AR [1]
Hydroxyflutamide displaced radiolabeled R1881 from wild-type AR in a whole-cell competition assay. The reported IC50 is a binding-assay endpoint, not a functional inhibition concentration or treatment dose.
Literature-Reported Treatment Conditions
- Treatment concentration
- Competitor concentration series shown in Figure 1B (log[M] axis); 0.1 nM [3H]-R1881
- Exposure duration
- 2 hours
- Method
- Whole-cell exposure followed by lysis and scintillation counting
- Co-treatment
- Radioligand competition with 0.1 nM [3H]-R1881
- Reported limits
- Assay vehicle and competitor-series bounds are not specified in the read methods/caption; no bounds inferred from graph ticks.
Methods and source locations
Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: OHF
Applies to the reported experimental material and model; no Adooq product or lot validation.
Figure 1A–B and caption; Results first subsection; Methods Reagents and Whole-cell competition assay
Displacement of 0.1 nM [3H]-R1881 from WT AR: Whole-cell radioligand competition; scintillation counts normalized to total protein. — Figure 1B legend within image and Results first subsection
Wild-type AR reporter response under R1881 cotreatment
Cell-based study · CV1 cells transiently expressing WT AR, MMTV-Luc and Renilla-Luc [1]
Hydroxyflutamide showed agonist behavior in this reporter model rather than suppressing androgen-driven reporter activity. Authors discuss high AR expression as a context for this result; causation is not established here.
Literature-Reported Treatment Conditions
- Treatment concentration
- Hydroxyflutamide concentration series in Figure 1C; 0.1 nM R1881
- Exposure duration
- 24 hours
- Method
- Transient AR reporter assay
- Co-treatment
- 0.1 nM R1881 cotreatment
- Reported limits
- Vehicle and exact hydroxyflutamide series are not specified in read methods/caption. No inhibitory IC50 adopted for an agonist response.
Methods and source locations
Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: OHF
Applies to the reported experimental material and model; no Adooq product or lot validation.
Figure 1C and caption; Results first subsection; Methods AR reporter gene assay
MMTV reporter response with 0.1 nM R1881: Dual-luciferase assay normalized to Renilla-Luc — Figure 1C and adjacent Results paragraph
Hydroxyflutamide binding in the T877A AR ligand-binding domain
Biochemical assay · Purified human AR ligand-binding domain (residues 663–919), T877A mutant; crystal structure 2AX6 [2]
The T877A–hydroxyflutamide structure shows a water-mediated interaction linking the ligand carbonyl and Leu-873 backbone oxygen. The authors propose that this interaction contributes to mutant-receptor agonism. A wild-type AR–hydroxyflutamide crystal structure was not obtained.
Literature-Reported Treatment Conditions
- Method
- X-ray crystallography of a purified ligand-bound receptor domain
- Reported limits
- No dosing or cellular exposure interpretation applies to crystallization. No WT–HF structure was available in this paper; no compound lot analytical certificate is provided in the read text.
Methods and source locations
Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: HF
Applies to the reported experimental material and model; no Adooq product or lot validation.
Table One, T877A-HF column; Figure 4d–e and caption; Results Ligand Interactions with Thr-877; crystallography methods and Discussion
T877A–HF crystal diffraction resolution range: X-ray crystallography; refinement started from W741L–R-bicalutamide structure 1Z95; ligand fitted to electron density — Table One, T877A-HF column
Water-mediated ligand interaction in T877A AR: Electron-density interpretation; Figure 4e displays 2Fo−Fc map at 1.5σ — Figure 4d–e and caption; Results Ligand Interactions with Thr-877
Growth response of LNCaP cells to hydroxyflutamide
Cell-based study · LNCaP human prostate cancer cells carrying AR T877A, in hormone-depleted medium [3]
At 1 μM for 72 hours, hydroxyflutamide increased the WST-1 signal relative to ethanol control. Mibolerone and cyproterone acetate also stimulated the growth-associated endpoint; bicalutamide did not.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM hydroxyflutamide
- Exposure duration
- 72 hours
- Method
- Ligand exposure following hormone depletion; WST-1 endpoint
- Vehicle
- Ethanol
- Co-treatment
- Single-agent hydroxyflutamide; separate comparator wells received 10 nM mibolerone or 1 μM cyproterone acetate or bicalutamide
- Reported limits
- Final ethanol percentage not stated in read methods. WST-1 measures metabolic activity and is not a direct cell-count endpoint.
Methods and source locations
Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: OHF
Applies to the reported experimental material and model; no Adooq product or lot validation.
Figure 1C and caption; Results Confirmation of Growth and Transcriptional Responses; Experimental Procedures Cell Culture, Hormones and Proliferation Assays
WST-1 growth-associated response relative to ethanol control: WST-1 mitochondrial dehydrogenase assay; representative of three independent experiments; eight wells per condition, displayed mean + SD — Figure 1C and caption; Proliferation Assays methods